{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
Basel, 16 March 2006\line \line {\b Roche update on Tamiflu 
for pandemic 
influenza preparedness} \line \line - Additional partners help boost Tamiflu 
production to 400 million 
treatments per year\line - Research initiatives on Tamiflu and the H5N1 virus identified \line \line Roche 
announces that it has further expanded its global manufacturing network for the production of Tamiflu 
and by the end of 2006, will have the capacity to produce up to 400 million treatments annually. This 
further ramp-up of capacity by 100 million treatments will be achieved through the addition of external 
production partners identified over the past few months as well as expansion in Roche owned facilities. 
\line \line Roche's global network for the manufacture of Tamiflu will include several 
Roche sites and more than 15 external contractors located in 9 different countries around the world. 
These production partners have been selected primarily on the basis of their ability to produce substantial 
quantities of intermediates and finished materials in accordance with Roche's quality standards in a 
relatively short time frame. Albemarle, Ampac Fine Chemicals LLC, API Corporation, Clariant, DSM, FIS, 
Martek Biosciences Corporation, Novasep/Dynamit Nobel, PHT International, PPG Industries, Sanofi-Aventis, 
Shaanxi Jiahe Phytochem Co and Siegfried Ltd are amongst the companies that will be involved in contributing 
to the overall production of Tamiflu.\line \line Roche is in final stage of negotiations 
for a sublicense with a company in China. Roche is also evaluating sharing of expertise in order to 
enable production in Africa. This is in addition to sub-licenses for the complete production of oseltamivir 
that were granted to Hetero and Shanghai Pharmaceuticals last year.\line \line William 
M.Burns, CEO Roche Pharma Division, said: "Following our open invitation to third parties last 
year, we have now identified partners who will allow us to expand the global Tamiflu capacity to as 
much as 400 million treatments annually by the end of this year. Of course, the rate at which this capacity 
is utilized will depend in large part on the future order flow from governments around the world. We 
are now ahead of demand in meeting the manufacturing challenge, but as a research based company, our 
role goes beyond this. We are committed to further expanding the knowledge base regarding Tamiflu and 
the H5N1 virus but we cannot do this alone and we need to collaborate with third parties moving forward\u8221?.\line {\b \line Research 
initiatives for H5N1} \line Roche has in place a number of research initiatives to answer 
questions 
raised on the use of Tamiflu against the evolving H5N1 avian virus. David Reddy, Roche\u8217?s Pandemic Task 
Force Leader, commented: \u8220?The H5N1 virus is continually changing. We know that the 1997 Hong Kong virus 
is different to the Vietnam virus and this in turn is different to the recent Turkey virus. For H5N1 
to be the next pandemic strain it must change again and extensive research needs to be carried out in 
this area so we have as much information as possible about the virus and Tamiflu to help us fight the 
pandemic threat when it fully emerges\u8221?. \line \line Research initiatives include:\line \u8226? 
Development of models to rapidly predict the response of emerging new viruses to Tamiflu\line \u8226? 
Studies to predict the optimum dose and duration of Tamiflu against different H5N1 subtypes \line \u8226? 
Long term prophylaxis against H5N1 for workers in essential activities, e.g. hospitals\line \u8226? 
Monitoring for resistance of the H5N1 virus to Tamiflu\line \line {\b \u8220?Call 
to Action\u8221? 
to the research community} \line Roche is seeking collaborations with clinicians/institutions 
involved in treating those infected with avian influenza to better understand the epidemiology and pathogenesis 
of this viral infection and to more systematically collect information regarding the use of Tamiflu 
in patients infected with H5N1. (Any relevant information should be mailed to research.tamiflu@roche.com (mailto://research.tamiflu@roche.com)).\line \line {\b Avian 
Influenza and Pandemics} \line The currently circulating H5N1 viruses in South East Asia 
and 
Turkey is extremely infective and transmissible in birds, and has induced a severe infection in humans, 
which results in deaths in an extremely high proportion (52%) of those infected. The World Health Organisation 
(WHO) has confirmed 177 cases in humans (March 13 2006) which resulted in 98 deaths. \line \line To 
date, transmission to humans has only occurred in people in close contact with infected birds and poultry 
farms, however, each new case does provide the virus with an opportunity to improve its transmissibility 
in humans increasing the risk of a human pandemic.\line \line {\b Roche\u8217?s 
efforts to 
support government pandemic stockpiling} \line The World Health Organization (WHO) advises 
that 
stockpiling antivirals in advance is presently the only way to ensure that sufficient supplies are available 
in the event of a pandemic. Roche has been working closely with WHO and national governments to ensure 
governments are aware of the importance of stockpiling antivirals in the event of a pandemic situation. 
Roche has received and fulfilled pandemic orders for Tamiflu from more than 65 countries worldwide. 
The magnitude of these orders varies with some countries, France, Finland, Iceland, Ireland, Luxembourg, 
Netherlands, New Zealand, Norway, Switzerland and UK stockpiling or intending to stockpile adequate 
Tamiflu to cover 20-40% of their population. Roche has also donated 5.125 million courses of Tamiflu 
treatment to the WHO for international rapid response and regional response to a pandemic influenza 
strain. \line \line {\b Roche and Gilead} \line Tamiflu 
was invented by Gilead 
Sciences and licensed to Roche in 1996. Roche and Gilead partnered on clinical development, with Roche 
leading efforts to produce, register and bring the product to the markets. Under the terms of the companies\u8217? 
agreement, amended in November 2005, Gilead participates with Roche in the consideration of sub-licenses 
for the pandemic supply of oseltamivir. To ensure broader access to Tamiflu for all patients in need, 
Gilead has agreed to waive its right to full royalty payments for product sold under these sub-licenses.\line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused 
healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products 
and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes 
on a broad range of fronts to improving people\u8217?s health and quality of life. Roche is a world leader 
in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader 
in virology. In 2005 sales by the Pharmaceuticals Division totalled 27.3 billion Swiss francs, and the 
Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 
150 countries and has R&D agreements and strategic alliances with numerous partners, including majority 
ownership interests in Genentech and Chugai. Additional information about the Roche Group is available 
on the Internet (www.roche.com (http://www.roche.com)).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in 
this release are legally protected.\par}\line \line {\b Additional 
information} \line - Roche Health Kiosk, Influenza (http://www.health-kiosk.ch/start_grip.htm)\line - 
About Tamiflu (http://www.roche.com/med_mbtamiflu05e.pdf)\line - About influenza (http://www.roche.com/med_mbinfluenza05e.pdf)\line - 
WHO: Global influenza programme (http://www.who.int/csr/disease/influenza/en/)\line - WHO: Avian flu (http://www.who.int/mediacentre/factsheets/avian_influenza/en/)
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}